GUWAHATI: An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of the Defence Research and Development Organisation(DRDO).
Defence Minister Rajnath Singh and Union Health Minister Dr Harsh Vardhan on Monday released the first batch of Anti-COVID drug 2DG developed by DRDO.
An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.
Defence Minister Rajnath Singh Tweeted, “Handed over the first batch of 2-DG anti Covid drug to the Union Health Minister @drharshvardhan after it was released today. This 2-DG drug developed by @DRDO_India & DRL is a perfect example of India’s scientific prowess and a milestone in the efforts towards self-reliance.”
Handed over the first batch of 2-DG anti Covid drug to the Union Health Minister @drharshvardhan after it was released today.
This 2-DG drug developed by @DRDO_India & DRL is a perfect example of India’s scientific prowess and a milestone in the efforts towards self-reliance. pic.twitter.com/oiuR2VVr2I
— Rajnath Singh (@rajnathsingh) May 17, 2021
Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from COVID-19.
Based on these results, Drugs Controller General of India’s (DCGI) Central Drugs Standard Control Organization (CDSCO) permitted Phase-II clinical trial of 2-DG in COVID-19 patients in May 2020.
